下載本文檔
版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEIbrutinib-biotinCat. No.: HY-100342CAS No.: 1599432-18-4分式: CHNOS分量: 1097.37作靶點(diǎn): Btk作通路: Protein Tyrosine Kinase/RTK儲(chǔ)存式: Pure form -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 50 mg/mL (45.56 mM; Ne
2、ed ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 0.9113 mL 4.5563 mL 9.1127 mL5 mM 0.1823 mL 0.9113 mL 1.8225 mL10 mM 0.0911 mL 0.4556 mL 0.9113 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液,并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn) 請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍福渲魄罢?qǐng)先配制澄清的儲(chǔ)備液,再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性,體內(nèi)實(shí)驗(yàn)的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存
3、條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占):1. 請(qǐng)依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (2.28 mM); Clear solution2. 請(qǐng)依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (2.28 mM); Clear solution3. 請(qǐng)依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (2.28 mM)
4、; Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 Ibrutinib-biotin種由 Ibrutinib 通過(guò)長(zhǎng)鏈接頭連接到物素上組成的探針,具體可參考WO2014059368A1 中 Compound 1-5,抑制 BTK,IC50 值為 0.755-1.02 nM。IC50 & Target IC50: 0.755-1.02 nM (BTK), 1.71-2.29 nM (TEC), 3.66-4.27 nM (BLK), 4.42-5.57 nM (BMX),
5、5.99-6.92 nM(LCK), 33.8-36.3 nM (Src), 0.187-0.198 M (ITK),5.34-4.87 M (JAK3) 1體外研究 Ibrutinib-biotin (Compound 1-5) is a probe that consists of Ibrutinib linked to biotin via a long chain linker.Ibrutinib is a TEC family kinase inhibitor. The TEC kinase family is composed of five members, TEC, BTK(B
6、rutons Tyrosine Kinase), ITK (interleukin-2-inducible T-cell kinase)/EMT/TSK, BMX and TXK/RLK. TheTEC family kinases participate in phosphotyrosine- mediated and phospholipid-mediated signaling systems.Many TEC family proteins are abundantly expressed in hematopoietic tissues, and play important rol
7、es in thegrowth and differentiation processes of blood cells 1.PROTOCOLKinase Assay 1 In this study, assay formats are tested for sensitivity, specificity, range, and to determine most suitable antiBTK Antibody. An aliquot of DOHH2 cell lysate (1 mg/mL) is inhibited with 1 M Ibrutinib then labeled w
8、ithprobe (1 M). Negative controls: Untreated DOHH2 and Jurkat cell lysates (l mg/mL) are labeled with probe(1 M) and Untreated DOHH2 cell lysate. Standard Streptavidin plate (5-pack); Read Buffer T (50 mL),SULFO TAG Goat Anti-mouse (50 g); SULFO TAG Goat Anti-rabbit (50 g); SULFO TAG streptavidin (5
9、0ug); MSD Standard Plates; MSD Blocker A; Protease inhibitor cocktail; Positive Control lysates from BTKexpressing cell line (DOHH2); Negative Control lysates; Ibrutinib (PCI); probe compound 1-5 (biotinylatedprobe).MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Betty Y. CHANG, et al. Companion diagnostics for tec family kinase inhibitor therapy. WO 2014059368 A1.McePdfHeightCaution: Product has not been fully validated for
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 水池挖方施工方案(3篇)
- 冰淇淋雪糕活動(dòng)策劃方案(3篇)
- 315晚會(huì)策劃活動(dòng)方案(3篇)
- 應(yīng)急預(yù)案視頻解讀(3篇)
- 國(guó)旗桿施工方案(3篇)
- 建筑施工方案推演(3篇)
- 民俗水電施工方案(3篇)
- 墻程施工方案(3篇)
- 兒科汛期應(yīng)急預(yù)案(3篇)
- 浙江項(xiàng)目施工方案(3篇)
- 券商投行部述職報(bào)告
- 金風(fēng)-綠電新政下風(fēng)電資產(chǎn)產(chǎn)銷(xiāo)一體新范式
- 2026屆湖南長(zhǎng)沙一中高一生物第一學(xué)期期末學(xué)業(yè)質(zhì)量監(jiān)測(cè)試題含解析
- PDLC薄膜性能的研究
- 一級(jí)2026年注冊(cè)建筑師之設(shè)計(jì)前期與場(chǎng)地設(shè)計(jì)考試題庫(kù)300道附參考答案【黃金題型】
- 三方協(xié)議書(shū)就業(yè)協(xié)議書(shū)
- 排水管網(wǎng)疏通與養(yǎng)護(hù)技術(shù)方案
- 肝內(nèi)膽管惡性腫瘤護(hù)理查房
- 2025-2026學(xué)年浙教版(2023)初中信息科技七年級(jí)上冊(cè)教學(xué)計(jì)劃及進(jìn)度表
- 昆明醫(yī)科大學(xué)海源學(xué)院《高等數(shù)學(xué)下》2024-2025學(xué)年第一學(xué)期期末試卷
- 中國(guó)特發(fā)性面神經(jīng)麻痹(面癱)治療指南(2022)解讀
評(píng)論
0/150
提交評(píng)論